Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.69% $3.05
America/New_York / 22 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 8.27 mill |
EPS: | -5.39 |
P/E: | -0.570 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 2.71 mill |
Avg Daily Volume: | 0.0030 mill |
RATING 2024-04-22 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.570 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.570 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.24 (6.17%) $0.188 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 2.80 - 3.30 ( +/- 8.23%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Chicko Rhonda M. | Sell | 0 | Common Stock |
2024-01-01 | Hecht Peter M | Buy | 15 000 | Common Stock |
2024-01-01 | Graul Regina Margaret | Buy | 50 000 | Common Stock |
2023-11-30 | Katabi Dina | Sell | 0 | Common Stock |
2023-11-30 | Higgins Michael J | Sell | 0 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 5 326 508 | Sell: 727 933 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $3.05 (2.69% ) |
Volume | 0.0001 mill |
Avg. Vol. | 0.0030 mill |
% of Avg. Vol | 3.39 % |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.